27/05/2026 FDA grants Fast Track to Solu’s STX‑0712 for relapsed/refractory CMML, advancing CyTAC™ platform into Phase 1 hematology trials FDA grants Fast Track to Solu’s STX‑0712 for relapsed/refractory CMML, advancing CyTAC™ platform into Phase 1 hematology trials (Ref) Solu Therapeutics’ investigational therapy STX-0712 has received Fast Track designation for relapsed/refractory chronic myelomonocytic leukemia (CMML) Ongoing Trials - A Phase 1, open-label, multicenter tria